Terns Pharmaceuticals Initiates $400 Million Public Offering
Public Offering Announcement: Terns Pharmaceuticals has launched a public offering of $400 million in common stock and pre-funded warrants for certain investors, with an option for underwriters to purchase an additional $60 million in shares.
Use of Proceeds: The company plans to use the net proceeds to support research, clinical development, and manufacturing for its key programs, particularly TERN-701, as well as for working capital and general corporate purposes.
Market Reaction: Following the announcement, Terns Pharma shares fell over 3% in pre-market trading after a significant increase of 37.02% the previous day.
Underwriters: Jefferies, TD Cowen, and Leerink Partners are serving as lead book-running managers for the offering.
Trade with 70% Backtested Accuracy
Analyst Views on TERN
About TERN
About the author
Viking Therapeutics CEO Highlights Broad Strategic Interest in Weight-Loss Drug Deals, Shares Surge 17%
- Stock Surge: Shares of Viking Therapeutics (VKTX) surged 17% on Wednesday, reflecting strong market interest in its weight-loss drug development, particularly as Novo Nordisk (NVO) seeks acquisitions to enhance its drug portfolio.
- M&A Activity: Novo Nordisk halted its $10 billion bid for the smaller obesity drugmaker Metsera, but successfully acquired Akero Therapeutics for up to $5.2 billion in December, indicating its aggressive strategy in the obesity drug market.
- Clinical Trial Progress: Viking's lead candidate VK2735 demonstrated a significant average weight loss of 14.7% over 13 weeks in mid-stage trials, showcasing its potential in obesity treatment, with ongoing studies for an oral formulation of the drug.
- Market Sentiment: On Stocktwits, retail sentiment around VKTX remained in the 'extremely bullish' territory, with message volume rising from 'high' to 'extremely high', as speculation grew about Novo potentially acquiring Viking for around $10 billion, which would represent substantial upside from its current near $4 billion market cap.
CleanSpark Inc. (CLSK) Jumps 14.13% Ahead of Mining Report for December 2025
- Stock Price Surge: CleanSpark's stock rose 14.13% on Friday to close at $11.55 per share, primarily driven by rising Bitcoin prices, reflecting investor optimism ahead of its upcoming December 2025 mining report.
- Bitcoin Mining Performance: In November, CleanSpark successfully mined 587 Bitcoins, bringing its total holdings to 13,054, indicating strong performance and ongoing growth potential in the Bitcoin market.
- Significant Sales Revenue: The company sold 565.41 Bitcoins at an average price of $91,979, generating total earnings of $52 million, which further solidifies its financial foundation in the Bitcoin mining sector.
- Strategic Transition: CleanSpark is gradually transitioning from Bitcoin mining to high-performance computing (HPC) services, and while the market remains optimistic about its future potential, analysts believe that other AI stocks may offer higher returns with lower risk.
Terns Pharmaceuticals Grants 312,000 Stock Options to New Employees
- Employee Incentive Program: As of January 1, 2026, Terns Pharmaceuticals granted 312,000 stock options to two new employees under the 2022 Employment Inducement Award Plan, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge.
- Option Details: The options have an exercise price of $40.40 per share, a 10-year term, and vest over four years, ensuring continued employee contributions during their tenure with the company.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in talent acquisition, which further boosts investor confidence.
- Strategic Implications: By implementing this incentive measure, Terns not only strengthens team stability but also maintains a competitive advantage in the clinical-stage oncology drug development sector, driving long-term growth for the company.
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
Terns Pharmaceuticals (TERN) Sees Price Target Raised by 75.91% to 54.63
Price Target Update: The average one-year price target for Terns Pharmaceuticals has been revised to $54.63 per share, reflecting a 75.91% increase from the previous estimate of $31.05. The new target range from analysts is between $17.17 and $73.50 per share.
Fund Sentiment: There are currently 271 funds reporting positions in Terns Pharmaceuticals, a decrease of 4.24% from the last quarter. The average portfolio weight for these funds has increased by 47.86%, with total shares owned by institutions rising by 6.16% to 94,932K shares.
Shareholder Activity: Soleus Capital Management has slightly reduced its holdings in Terns Pharmaceuticals, while other major shareholders like Orbimed Advisors and Deep Track Capital have maintained their positions. Commodore Capital has significantly increased its stake by 100%.
Research Platform: Fintel provides comprehensive investing research tools, including fundamentals, analyst reports, ownership data, and options sentiment, aimed at individual investors and small hedge funds for improved investment decisions.
Cramer's Lighting Round: Exercise Caution with Lumen Technologies
Drone Technology: Caution is advised regarding drone technology investments due to high speculation and significant financial losses.
TopBuild: The insulation market is promising, but there is a suggestion to take profits after a strong performance.
Horizon Technology Finance: Lack of transparency in the company's holdings raises trust issues, making it a non-recommendation.
Lumen Technologies: The stock has seen substantial gains, prompting a warning to exercise caution with future investments.
Viking Therapeutics CEO Highlights Broad Strategic Interest in Weight-Loss Drug Deals, Shares Surge 17%
- Stock Surge: Shares of Viking Therapeutics (VKTX) surged 17% on Wednesday, reflecting strong market interest in its weight-loss drug development, particularly as Novo Nordisk (NVO) seeks acquisitions to enhance its drug portfolio.
- M&A Activity: Novo Nordisk halted its $10 billion bid for the smaller obesity drugmaker Metsera, but successfully acquired Akero Therapeutics for up to $5.2 billion in December, indicating its aggressive strategy in the obesity drug market.
- Clinical Trial Progress: Viking's lead candidate VK2735 demonstrated a significant average weight loss of 14.7% over 13 weeks in mid-stage trials, showcasing its potential in obesity treatment, with ongoing studies for an oral formulation of the drug.
- Market Sentiment: On Stocktwits, retail sentiment around VKTX remained in the 'extremely bullish' territory, with message volume rising from 'high' to 'extremely high', as speculation grew about Novo potentially acquiring Viking for around $10 billion, which would represent substantial upside from its current near $4 billion market cap.
CleanSpark Inc. (CLSK) Jumps 14.13% Ahead of Mining Report for December 2025
- Stock Price Surge: CleanSpark's stock rose 14.13% on Friday to close at $11.55 per share, primarily driven by rising Bitcoin prices, reflecting investor optimism ahead of its upcoming December 2025 mining report.
- Bitcoin Mining Performance: In November, CleanSpark successfully mined 587 Bitcoins, bringing its total holdings to 13,054, indicating strong performance and ongoing growth potential in the Bitcoin market.
- Significant Sales Revenue: The company sold 565.41 Bitcoins at an average price of $91,979, generating total earnings of $52 million, which further solidifies its financial foundation in the Bitcoin mining sector.
- Strategic Transition: CleanSpark is gradually transitioning from Bitcoin mining to high-performance computing (HPC) services, and while the market remains optimistic about its future potential, analysts believe that other AI stocks may offer higher returns with lower risk.
Terns Pharmaceuticals Grants 312,000 Stock Options to New Employees
- Employee Incentive Program: As of January 1, 2026, Terns Pharmaceuticals granted 312,000 stock options to two new employees under the 2022 Employment Inducement Award Plan, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge.
- Option Details: The options have an exercise price of $40.40 per share, a 10-year term, and vest over four years, ensuring continued employee contributions during their tenure with the company.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in talent acquisition, which further boosts investor confidence.
- Strategic Implications: By implementing this incentive measure, Terns not only strengthens team stability but also maintains a competitive advantage in the clinical-stage oncology drug development sector, driving long-term growth for the company.
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
Terns Pharmaceuticals (TERN) Sees Price Target Raised by 75.91% to 54.63
Price Target Update: The average one-year price target for Terns Pharmaceuticals has been revised to $54.63 per share, reflecting a 75.91% increase from the previous estimate of $31.05. The new target range from analysts is between $17.17 and $73.50 per share.
Fund Sentiment: There are currently 271 funds reporting positions in Terns Pharmaceuticals, a decrease of 4.24% from the last quarter. The average portfolio weight for these funds has increased by 47.86%, with total shares owned by institutions rising by 6.16% to 94,932K shares.
Shareholder Activity: Soleus Capital Management has slightly reduced its holdings in Terns Pharmaceuticals, while other major shareholders like Orbimed Advisors and Deep Track Capital have maintained their positions. Commodore Capital has significantly increased its stake by 100%.
Research Platform: Fintel provides comprehensive investing research tools, including fundamentals, analyst reports, ownership data, and options sentiment, aimed at individual investors and small hedge funds for improved investment decisions.
Cramer's Lighting Round: Exercise Caution with Lumen Technologies
Drone Technology: Caution is advised regarding drone technology investments due to high speculation and significant financial losses.
TopBuild: The insulation market is promising, but there is a suggestion to take profits after a strong performance.
Horizon Technology Finance: Lack of transparency in the company's holdings raises trust issues, making it a non-recommendation.
Lumen Technologies: The stock has seen substantial gains, prompting a warning to exercise caution with future investments.
